ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.3313A>T (p.Lys1105Ter)

dbSNP: rs1555614867
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Human Genetics, Inc, Center for Human Genetics, Inc RCV000660032 SCV000781979 likely pathogenic Neurofibromatosis, type 1 2016-11-01 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000660032 SCV002195817 pathogenic Neurofibromatosis, type 1 2021-10-29 criteria provided, single submitter clinical testing This variant has not been reported in the literature in individuals affected with NF1-related conditions. This sequence change creates a premature translational stop signal (p.Lys1105*) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 547625). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Genome-Nilou Lab RCV000660032 SCV002559948 pathogenic Neurofibromatosis, type 1 2022-03-15 criteria provided, single submitter clinical testing
Ambry Genetics RCV004993919 SCV005459485 pathogenic Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2024-10-16 criteria provided, single submitter clinical testing The p.K1105* pathogenic mutation (also known as c.3313A>T), located in coding exon 25 of the NF1 gene, results from an A to T substitution at nucleotide position 3313. This changes the amino acid from a lysine to a stop codon within coding exon 25. This variant has been observed in at least one individual with a personal and/or family history that is consistent with neurofibromatosis type 1 (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.